New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2014
08:26 EDTRHHBY, ACTCHMP adopts positive opinion on Actavis generic version of Roche's Tamiflu
The EMA's Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ebilfumin 30 mg, 45 mg and 75 mg, hard capsules intended for the treatment and prevention of influenza. The applicant for this medicinal product is Actavis (ACT). Ebilfumin is a generic of Roche's (RHHBY) Tamiflu.
News For ACT;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 28, 2015
08:24 EDTACTActavis added to Focus List with $360 target at Citigroup
Subscribe for More Information
08:21 EDTRHHBYAmgen could be hurt by Roche deal, says RBC Capital
Subscribe for More Information
May 27, 2015
19:14 EDTACTOn The Fly: After Hours Movers
Subscribe for More Information
17:34 EDTACTActavis receives FDA approval for VIBERZI for treatment of IBS-D
Subscribe for More Information
08:33 EDTRHHBYHalozyme and Ventana enter into global agreement to develop companion diagnostic
Halozyme (HALO) and Ventana Medical Systems, a member of the Roche (RHHBY), announced a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20. The Ventana assay will be used to identify high levels of hyaluronan. HA is a glycosaminoglycan that can accumulate around cancer cells. Halozyme has announced plans for rollout of a global phase 3 clinical study in 2016 targeting metastatic pancreatic cancer patients with high HA levels using its PEGPH20 in combination with ABRAXANE and gemcitabine. Under the agreement, Ventana will develop an in vitro diagnostic, under design control, using Halozyme's proprietary HA binding protein, with the intent of submitting it for regulatory approval in the United States, Europe and other countries. The financial terms of the agreement were not disclosed.
May 22, 2015
16:07 EDTACTActavis confirms court ruling requiring continued distribution of NAMENDA IR
Actavis confirmed that a panel of the U.S. Court of Appeals for the Second Circuit has issued a ruling upholding a December 15, 2014 preliminary injunction requiring the company to continue distribution of NAMENDA immediate-release tablets. Actavis noted that the company will continue to manage sales and R&D expenses to ensure that the Appeals court's decision will have minimal to no impact on its 2015 NAMENDA franchise contribution to earnings and longer term company earnings aspirations.
13:19 EDTACTNY AG says ruling on Actavis Alzheimer’s drug a victory for patients
New York Attorney General Eric Schneiderman, following a decision by the U.S. Court of Appeals for the Second Circuit to affirm the federal district court decision granting New York’s motion for a preliminary injunction against defendants Actavis and Forest Laboratories, stated: "Today’s appeals court decision is a sweeping victory for consumers and Alzheimer’s patients. Our lawsuit and the court’s injunction protect competition and prevent Actavis from coercing Alzheimer’s patients into taking drugs they do not want in order to charge them monopoly prices...My office will continue to protect New Yorkers from anticompetitive practices by drug manufacturers.”
11:26 EDTACTCourt rules Actavis can't pull Alzheimer's drug for pricer new one, Reuters says
A three-judge panel of a New York appeals court upheld a prior order requiring Actavis to keep the older version of its Alzheimer's drug, Namenda IR, on the market following the company's launch of a more expensive extended-release version, reported Reuters. Reference Link
11:23 EDTACTCourt rules Actavis can't pull Alzheimer's drug for pricer new one, Reuters says
Subscribe for More Information
10:52 EDTACT, RHHBYJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
07:44 EDTACTActavis trades at over 20% discount to Major Pharma, says JPMorgan
Subscribe for More Information
May 21, 2015
07:37 EDTRHHBYPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 18, 2015
16:07 EDTRHHBYIllumina files new patent infringement suit against Roche unit
Subscribe for More Information
11:21 EDTACTAckman sold out of Actavis stake after Q1 report, NY Post says
Subscribe for More Information
10:01 EDTRHHBYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: A10 Networks (ATEN) upgraded to Overweight from Sector Weight at Pacific Crest... Cal-Maine Foods (CALM) upgraded to Overweight from Equal Weight at Stephens... ChemoCentryx (CCXI) upgraded to Overweight from Neutral at JPMorgan... Cheniere Energy Partners LP (CQP) upgraded to Buy from Neutral at Goldman... Chicago Bridge & Iron (CBI) upgraded to Neutral from Sell at Goldman... Continental Resources (CLR) upgraded to Buy from Neutral at Goldman... Ctrip.com (CTRP) upgraded to Overweight from Neutral at JPMorgan... Emerge Energy (EMES) upgraded to Buy from Neutral at Goldman... FEMSA (FMX) upgraded to Overweight from Equal Weight at Morgan Stanley... GoPro (GPRO) upgraded to Perform from Underperform at Oppenheimer... Holly Energy (HEP) upgraded to Buy from Neutral at Goldman... JP Energy (JPEP) upgraded on better visibility on volumes at RBC Capital... Laredo Petroleum (LPI) upgraded to Neutral from Sell at Goldman... Malvern Bancorp (MLVF) upgraded to Outperform from Market Perform at Keefe Bruyette... Newfield Exploration (NFX) upgraded to Buy from Neutral at Goldman... Norsk Hydro (NHYDY) upgraded to Overweight from Neutral at JPMorgan... Owens-Illinois (OI) upgraded to Neutral from Underperform at BofA/Merrill... Penn National (PENN) upgraded to Buy from Neutral at Goldman... Roche (RHHBY) upgraded to Buy from Neutral at UBS... Schnitzer Steel (SCHN) upgraded on stabilizing headwinds at KeyBanc... Seventy Seven Energy (SSE) upgraded to Buy from Hold at Jefferies... Toll Brothers (TOL) upgraded to Neutral from Underperform at Sterne Agee CRT... United Therapeutics (UTHR) upgraded to Buy from Neutral at BTIG... Volvo (VOLVY) upgraded to Neutral from Underweight at JPMorgan... Zayo Group (ZAYO) upgraded to Buy from Neutral at Goldman.
09:23 EDTRHHBYRoche upgraded to Buy from Neutral at UBS
Subscribe for More Information
08:01 EDTACTActavis launches Namzaric to treat moderate to severe Alzheimer's
Actavis announced that NAMZARIC, a once-daily, fixed-dose combination of memantine hydrochloride extended-release, and donepezil hydrochloride, is now available to patients and healthcare professionals across the United States. NAMZARIC was approved by the FDA in December for the treatment of moderate to severe Alzheimer's disease in patients stabilized on memantine hydrochloride and donepezil hydrochloride.
07:22 EDTACTUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 18 at 8 am; not all company presentations may be webcasted. Webcast Link
07:15 EDTACTPhysician feedback on Actavis Eluxadoline positive, says RBC Capital
After conducting a survey, RBC Capital says that physician enthusiasm about Actavis' Eluxadoline is high ahead of its expected early 2016 launch. The firm thinks the drug could be an important P&L driver for the company and keeps a Top Pick rating on the shares.
06:58 EDTACTActavis CEO says chances of Pfizer offer are 'unlikely', Financial Times says
Actavis (ACT) CEO Brent Saunders said the chances of Pfizer (PFE) making an offer are "incredibly unlikely," reports the Financial Times. Saunders said he has heard the gossip that Actavis could become a takeover target for a larger group, but he spends "zero time thinking about it." Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use